Free Trial

Leerink Partnrs Upgrades AbCellera Biologics (NASDAQ:ABCL) to Strong-Buy

AbCellera Biologics logo with Medical background

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) was upgraded by equities research analysts at Leerink Partnrs to a "strong-buy" rating in a research note issued to investors on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for AbCellera Biologics' Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.64) EPS and FY2026 earnings at ($0.28) EPS.

A number of other research firms also recently commented on ABCL. KeyCorp increased their target price on shares of AbCellera Biologics from $4.00 to $5.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. Leerink Partners began coverage on shares of AbCellera Biologics in a research report on Monday. They issued an "outperform" rating and a $5.00 target price on the stock. Finally, Truist Financial dropped their target price on shares of AbCellera Biologics from $28.00 to $10.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $7.50.

Read Our Latest Research Report on ABCL

AbCellera Biologics Stock Performance

Shares of NASDAQ:ABCL traded up $0.33 during trading hours on Monday, reaching $4.22. The stock had a trading volume of 6,979,281 shares, compared to its average volume of 3,462,229. AbCellera Biologics has a 1 year low of $1.89 and a 1 year high of $4.29. The firm's 50 day moving average is $2.72 and its 200-day moving average is $2.74. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of -7.54 and a beta of 0.62.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.02. The company had revenue of $4.24 million for the quarter, compared to the consensus estimate of $7.12 million. AbCellera Biologics had a negative net margin of 737.56% and a negative return on equity of 15.98%. Analysts forecast that AbCellera Biologics will post -0.59 EPS for the current year.

Institutional Trading of AbCellera Biologics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Stratos Wealth Advisors LLC purchased a new stake in shares of AbCellera Biologics in the first quarter valued at about $27,000. DKM Wealth Management Inc. purchased a new stake in shares of AbCellera Biologics in the fourth quarter valued at about $29,000. Janney Montgomery Scott LLC purchased a new stake in shares of AbCellera Biologics in the first quarter valued at about $29,000. AssuredPartners Investment Advisors LLC purchased a new stake in shares of AbCellera Biologics in the first quarter valued at about $34,000. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of AbCellera Biologics in the fourth quarter valued at about $40,000. Hedge funds and other institutional investors own 61.42% of the company's stock.

About AbCellera Biologics

(Get Free Report)

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.

Featured Articles

Analyst Recommendations for AbCellera Biologics (NASDAQ:ABCL)

Should You Invest $1,000 in AbCellera Biologics Right Now?

Before you consider AbCellera Biologics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.

While AbCellera Biologics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines